Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

Clinical Neuropharmacology

Volumn 24, Issue 5, 2001, Pages 295-299

  Factor, Stewart A ^a   Molho, Eric S ^a   Feustel, Paul J ^a   Brown, Diane L ^a   Evans, Sharon M ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

Catechol O methyltransferase inhibitors; Entacapone; Parkinson's disease; Tolcapone

Indexed keywords

ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; TOLCAPONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; LONG TERM CARE; MALE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0034816337     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200109000-00007     Document Type: Article

References (11)

1. COMT inhibitors: Pharmacokinetic and pharmacodynamic comparisons
2. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
3. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating patients with PD
4. Tolcapone improves motor function in patients with PD with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial
5. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: A multicenter, double-blind, randomized, placebo-controlled trial
6. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa
7. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients
8. Entacapone enhances the response to levodopa in patients with PD with motor fluctuations
9. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors
10. Tolcapone and hepatotoxic effects
11. Hepatic safety of the COMT inhibitor entacapone